Thomas Fremming Dejgaard
Thomas Fremming Dejgaard
Steno Diabetes Center Copenhagen
Bekræftet mail på dadlnet.dk
Titel
Citeret af
Citeret af
År
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo …
TF Dejgaard, CS Frandsen, TS Hansen, T Almdal, S Urhammer, ...
The lancet Diabetes & endocrinology 4 (3), 221-232, 2016
952016
Changes in insulin sensitivity precede changes in body composition during 14 days of step reduction combined with overfeeding in healthy young men
SH Knudsen, LS Hansen, M Pedersen, T Dejgaard, J Hansen, GV Hall, ...
Journal of applied physiology 113 (1), 7-15, 2012
932012
Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus
CS Frandsen, TF Dejgaard, S Madsbad
The Lancet Diabetes & Endocrinology 4 (9), 766-780, 2016
732016
Twelve-week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind …
CS Frandsen, TF Dejgaard, JJ Holst, HU Andersen, B Thorsteinsson, ...
Diabetes Care 38 (12), 2250-2257, 2015
642015
Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy
T Hvid, K Winding, A Rinnov, T Dejgaard, C Thomsen, P Iversen, ...
Endocrine-related cancer 20 (5), 621-632, 2013
242013
Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo …
CS Frandsen, TF Dejgaard, HU Andersen, JJ Holst, B Hartmann, ...
Diabetes, Obesity and Metabolism 19 (6), 773-782, 2017
172017
Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a …
TF Dejgaard, FK Knop, L Tarnow, CS Frandsen, TS Hansen, T Almdal, ...
BMJ open 5 (4), 2015
152015
Emerging drugs for the treatment of obesity
C Martinussen, KN Bojsen-Moller, MS Svane, TF Dejgaard, S Madsbad
Expert opinion on emerging drugs 22 (1), 87-99, 2017
142017
Liraglutide for treating type 1 diabetes
TF Dejgaard, CS Frandsen, JJ Holst, S Madsbad
Expert Opinion on Biological Therapy 16 (4), 579-590, 2016
142016
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
NJ Johansen, TF Dejgaard, A Lund, C Schlüntz, CS Frandsen, JL Forman, ...
The Lancet Diabetes & Endocrinology, 2020
112020
Duration and complications of diabetes mellitus and the associated risk of infective endocarditis
L Østergaard, UM Mogensen, JS Bundgaard, A Dahl, A Wang, ...
International Journal of Cardiology 278, 280-284, 2019
112019
Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy
J Fleischer, E Laugesen, SL Cichosz, P Hoeyem, TF Dejgaard, ...
Journal of Diabetes and its Complications 31 (9), 1389-1393, 2017
92017
Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes
TF Dejgaard, NB Johansen, CS Frandsen, A Asmar, L Tarnow, FK Knop, ...
Diabetes, Obesity and Metabolism 19 (5), 734-738, 2017
92017
Fixed-ratio combination therapy with GLP-1 receptor agonist liraglutide and insulin degludec in people with type 2 diabetes
L Østergaard, CS Frandsen, TF Dejgaard, S Madsbad
Expert Review of Clinical Pharmacology 10 (6), 621-632, 2017
82017
Non-insulin pharmacological therapies for treating type 1 diabetes
CS Frandsen, TF Dejgaard, S Madsbad, JJ Holst
Expert opinion on pharmacotherapy 19 (9), 947-960, 2018
72018
Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double …
TF Dejgaard, S Schmidt, CS Frandsen, D Vistisen, S Madsbad, ...
Diabetes, Obesity and Metabolism 22 (4), 492-500, 2020
62020
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo …
TF Dejgaard, CS Frandsen, TS Hansen, T Almdal, S Urhammer, ...
A RCT in overweight adult individuals with T1D showing that addition of …, 0
5
59-OR: Liraglutide Preserved Insulin Secretion in Adults with Newly Diagnosed Type 1 Diabetes: The NewLira Trial
TF Dejgaard, CS Frandsen, U Kielgast, HU Andersen, B Thorsteinsson, ...
Diabetes 68 (Supplement 1), 2019
42019
The efficacy and safety of exenatide once weekly in patients with type 2 diabetes
SM Heimbürger, A Brønden, NJ Johansen, TF Dejgaard, T Vilsbøll, ...
Expert opinion on pharmacotherapy 20 (5), 501-510, 2019
42019
The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): A multi-arm, randomised …
K Færch, MB Blond, L Bruhn, H Amadid, D Vistisen, KKB Clemmensen, ...
Diabetologia 64 (1), 42-55, 2021
32021
Systemet kan ikke foretage handlingen nu. Prøv igen senere.
Artikler 1–20